Quest sells royalty rights to cancer drug ibrutinib for $485M

07/19/2013 | Genetic Engineering & Biotechnology News

Royalty Pharma agreed to pay $485 million in cash to acquire Quest Diagnostics' royalty rights from commercialization of ibrutinib, a drug candidate for chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma. The drug is being jointly developed by Pharmacyclics and Janssen Biotech. Quest obtained the royalty rights as part of its purchase of Celera in 2011.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD